Fulgent Genetics, Inc. (FLGT) News
Track canonical SquawkNews coverage tagged to FLGT, Fulgent Genetics, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 6 indexed stories across 2 publication days and is ordered by the same first-publication timeline used by LiveCast.
H
Apple, Stryker, Coinbase And Other Big Stocks Moving Lower In Friday’s Pre-Market Session
U.S. stock futures were higher this morning, with the Nasdaq 100 futures gaining around 300 points on Friday. Shares of Apple Inc (NASDAQ: AAPL ) fell sharply in pre-market trading after the company posted results for th
EARNINGS | Jul 31, 2026, 12:03 PM UTC
L
FLGT (more) Earnings Notes: - Fulgent Genetics Q2 ADJ EPS $-0.58 - Expects 2026 REV $330.0-$340.0M; non-GAAP loss of about $2.22-$2.35 per s
FLGT (more) Earnings Notes: - Fulgent Genetics Q2 ADJ EPS $-0.58 - Expects 2026 REV $330.0-$340.0M; non-GAAP loss of about $2.22-$2.35 per share
EARNINGS | Jul 30, 2026, 08:20 PM UTC
L
Fulgent Genetics Lowers FY2026 Adj EPS Guidance from $(1.59) to $(2.35)-$(2.22) vs $(1.55) Est; Lowers FY2026 Sales Guidance from $350.000M
Fulgent Genetics (NASDAQ: FLGT ) lowers FY2026 Adj EPS guidance from $(1.59) to $(2.35)-$(2.22) vs $(1.55) analyst estimate. Lowers FY2026 sales outlook from $350.000 million to $330.000 million-$340.000 million vs $351.
EARNINGS | Jul 30, 2026, 08:19 PM UTC
H
MYGN -29%, RBLX -11.6%, FLGT -10.7%, VCYT -9.8%, SYK -9.5%, ALHC -8.6%, COIN -6.5%, RDDT -5.8%, GSIT -5.3%, IR -3.1% after results
MYGN -29%, RBLX -11.6%, FLGT -10.7%, VCYT -9.8%, SYK -9.5%, ALHC -8.6%, COIN -6.5%, RDDT -5.8%, GSIT -5.3%, IR -3.1% after results
EARNINGS | Jul 30, 2026, 08:15 PM UTC
L
FLGT - Fulgent Reports Second Quarter 2026 Financial Results
FLGT - Fulgent Reports Second Quarter 2026 Financial Results
EARNINGS | Jul 30, 2026, 08:10 PM UTC
L
FLGT Fulgent Genetics RESULTS: Q2, Q2 operating expenses $61.752M, Q2 Operating Income $-36.073M, Q2 pretax profit $-29.69M, Q2 gross profit
FLGT Fulgent Genetics RESULTS: Q2, Q2 operating expenses $61.752M, Q2 Operating Income $-36.073M, Q2 pretax profit $-29.69M, Q2 gross profit $25.679M, Q2 REV $85.389M, Q2 ADJ EBITDA $-17.1M
EARNINGS | Jul 30, 2026, 08:06 PM UTC